Search Results 291-300 of 14738 for anti-TNF drugs

1. Ixekizumab (Subcutaneous Route) Description and Brand Names - Mayo Clinic

   Ixekizumab injection is used to treat moderate-to-severe plaque psoriasis in patients who may benefit from receiving phototherapy (ultraviolet light treatment) ...

2. Safety and Immune Response of the COVID 19 Vaccine in Patients with Inflammatory Bowel Disease - Mayo Clinic

   ustekinumab mono or combination therapy;; patients on mesalamine or no therapy. Group B (Low vaccine responders):. Anti-TNF monotherapy;; anti-TNF combination ...

3. Theophylline And Guaifenesin (Oral Route) Before Using - Mayo Clinic

   Adalimumab; Adenosine; Amifampridine; Bupropion ... drugs may be the best treatment for you. If both ... Certain medicines should not be used at or ...

4. Tailored Antiplatelet Therapy Following PCI - Mayo Clinic

   Clopidogrel is an anti-platelet medication approved by the U.S. Federal Drug Administration (FDA) for use in patients who undergo Percutaneous Coronary ...

5. Kidney Transplant Program - Steroid-free immunosuppression protocols - Mayo Clinic

   Mayo Clinic doctors prescribe many types of immunosuppressive (anti-rejection) medications, which may include steroid-free immunosuppression protocols. In ...

6. Tocilizumab-Aazg (Intravenous Route, Subcutaneous Route) Description and Brand Names - Mayo Clinic

   Tocilizumab-aazg injection is used alone or together with other medicines to treat moderate to severe active rheumatoid arthritis in patients who have been ...

7. Measles - Diagnosis & treatment - Mayo Clinic

   Medications. Treatment for a measles infection may include: Fever reducers. If a fever is making you or your child uncomfortable, you can use ...

8. Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD) - Mayo Clinic

   Demonstrated intolerance or inadequate response to one or more anti-tumor necrosis factor (TNF) therapies. Exclusion Criteria: Current diagnosis of ...

9. A Study to Evaluate the Safety and Effectiveness of PF-06650833, PF-06700841, and PF 06826647 in Adults With Hidradenitis Suppurativa Evaluating the Safety and Effectiveness of PF-06650833, PF-06700841, and PF-06826647 in Adults with Moderate-to-Severe Hidradenitis Suppurativa - Mayo Clinic

   Drugs & Supplements A-Z · Health Books · Healthy Living Program · Mayo Clinic ... Anti-TNF naïve; or Has initiated only one anti-TNF treatment including ...

10. Science Saturday: Researchers explore personalized approach to anti-obesity medications

    Acosta and a team of Mayo Clinic researchers set out to study anti-obesity medications based on obesity phenotypes to enhance weight loss. A phenotype is a set ...